CoChat

Diagnostic Accuracy of FibroScan and Factors Affecting Measurements

Open access
Oeda, Satoshi, Tanaka, Kenichi, Oshima, Ayaka, Matsumoto, Yasue, Sueoka, Eisaburo, Takahashi, Hirokazu · 2020 · Diagnostics
Cited by 123

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Evaluating liver steatosis and fibrosis is important for patients with non-alcoholic fatty liver disease. Although liver biopsy and pathological assessment is the gold standard for these conditions, this technique has several disadvantages. The evaluation of steatosis and fibrosis using ultrasound B-mode imaging is qualitative and subjective. The liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) determined using FibroScan are the evidence-based non-invasive measures of liver fibrosis and steatosis, respectively. The LSM and CAP measurements are carried out simultaneously, and the median values of more than ten valid measurements are used to quantify liver fibrosis and steatosis. Here, we demonstrate that the reliability of the LSM depends on the interquartile range to median ratio (IQR/Med), but CAP values do not depend on IQR/Med. In addition, the LSM is affected by inflammation, congestion, and cholestasis in addition to fibrosis, while CAP values are affected by the body mass index in addition to steatosis. We also show that the M probe provides higher LSM values but lower CAP values than the XL probe in the same population. However, there was no statistically significant difference between the diagnostic accuracies of the two probes. These findings are important to understand the reliability of FibroScan measurements and the factors influencing measurement values for all patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics10110940

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 66

  1. Bedossa, 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
  2. Angulo, 2015, Liver Fibrosis, but No Other Histologic Features, Is Associated with Long-term Outcomes of Patients with Nonalcoholic Fatty Liver Disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 · DOI · Paper page
  3. Piccinino, 1986, Complications following percutaneous liver biopsy, J. Hepatol., 2, 165, 10.1016/S0168-8278(86)80075-7 · DOI · Paper page
  4. Ratziu, 2005, Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease, Gastroenterology, 128, 1898, 10.1053/j.gastro.2005.03.084 · DOI · Paper page
  5. Kuwashiro, 2019, Discordant pathological diagnosis of non-alcoholic fatty liver disease: A prospective multicenter study, JGH Open, 4, 497, 10.1002/jgh3.12289 · DOI
  6. Tincopa, 2020, Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis, Endocrinol. Diabetes Metab., 3, 00177, 10.1002/edm2.177 · DOI
  7. Yajima, 1983, Ultrasonographical Diagnosis of Fatty Liver: Significance of the Liver-Kidney Contrast, Tohoku J. Exp. Med., 139, 43, 10.1620/tjem.139.43 · DOI · Paper page
  8. Marshall, 2012, Hepatorenal Index as an Accurate, Simple, and Effective Tool in Screening for Steatosis, Am. J. Roentgenol., 199, 997, 10.2214/AJR.11.6677 · DOI
  9. Shen, 2006, Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis, World J. Gastroenterol., 12, 1292, 10.3748/wjg.v12.i8.1292 · doi:10.3748/wjg.v12.i8.1292
  10. Yoneda, M., Honda, Y., Nogami, A., Imajo, K., and Nakajima, A. (2020). Advances in ultrasound elastography for nonalcoholic fatty liver disease. J. Med Ultrason., 1–13. · DOI
  11. Honda, Y., Yoneda, M., Imajo, K., and Nakajima, A. (2020). Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Int. J. Mol. Sci., 21. · DOI
  12. Hsu, 2019, Magnetic Resonance vs Transient Elastography Analysis of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants, Clin. Gastroenterol. Hepatol., 17, 630, 10.1016/j.cgh.2018.05.059 · DOI · Paper page
  13. Zhang, 2019, Application of transient elastography in nonalcoholic fatty liver disease, Clin. Mol. Hepatol., 26, 128, 10.3350/cmh.2019.0001n · DOI
  14. Newsome, 2020, FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study, Lancet Gastroenterol. Hepatol., 5, 362, 10.1016/S2468-1253(19)30383-8 · DOI · Paper page
  15. Oeda, 2020, Diagnostic accuracy of FibroScan-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes, Hepatol. Res., 50, 831, 10.1111/hepr.13508 · DOI
  16. Eslam, M., Sarin, S.K., Wong, V.W.-S., Fan, J.-G., Kawaguchi, T., Ahn, S.H., Zheng, M.-H., Shiha, G., Yilmaz, Y., and Gani, R. (2020). The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. · DOI · Paper page
  17. Chan, 2016, Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population, United Eur. Gastroenterol. J., 5, 76, 10.1177/2050640616646528 · DOI · Paper page
  18. Yoneda, 2007, Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD), Gut, 56, 1330, 10.1136/gut.2007.126417 · DOI · Paper page
  19. Yoneda, 2008, Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD), Dig. Liver Dis., 40, 371, 10.1016/j.dld.2007.10.019 · DOI · Paper page
  20. Nobili, 2008, Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis, Hepatology, 48, 442, 10.1002/hep.22376 · DOI · Paper page
  21. Badea, 2010, Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis, J. Gastrointest. Liver Dis., 19, 53
  22. Kriener, 2010, Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis, Eur. Radiol., 20, 2390, 10.1007/s00330-010-1820-9 · DOI
  23. Petta, 2011, Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index, Aliment. Pharmacol. Ther., 33, 1350, 10.1111/j.1365-2036.2011.04668.x · DOI · Paper page
  24. Romen, 2012, Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD, Eur. J. Radiol., 81, e325, 10.1016/j.ejrad.2011.10.029 · DOI · Paper page
  25. Kumar, 2013, Liver Stiffness Measurements in Patients with Different Stages of Nonalcoholic Fatty Liver Disease: Diagnostic Performance and Clinicopathological Correlation, Dig. Dis. Sci., 58, 265, 10.1007/s10620-012-2306-1 · DOI
  26. Pathik, 2015, Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from Western India, Ann. Gastroenterol., 28, 281
  27. Imajo, 2016, Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography, Gastroenterology, 150, 626, 10.1053/j.gastro.2015.11.048 · DOI · Paper page
  28. Eddowes, 2019, Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042 · DOI · Paper page
  29. Oeda, 2019, Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: A multicenter prospective study, J. Gastroenterol., 55, 428, 10.1007/s00535-019-01635-0 · DOI
  30. Cardoso, 2020, The performance of M and XL probes of FibroScan for the diagnosis of steatosis and fibrosis on a Brazilian nonalcoholic fatty liver disease cohort, Eur. J. Gastroenterol. Hepatol., 32, 231, 10.1097/MEG.0000000000001496 · DOI
  31. Lucidarme, 2008, Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C, Hepatology, 49, 1083, 10.1002/hep.22748 · DOI · Paper page
  32. Kettaneh, 2007, Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients, J. Hepatol., 46, 628, 10.1016/j.jhep.2006.11.010 · DOI · Paper page
  33. Coco, 2007, Transient elastography: A new surrogate marker of liver fibrosis influenced by major changes of transaminases, J. Viral Hepat., 14, 360, 10.1111/j.1365-2893.2006.00811.x · DOI · Paper page
  34. Arena, 2007, Acute viral hepatitis increases liver stiffness values measured by transient elastography, Hepatology, 47, 380, 10.1002/hep.22007 · DOI · Paper page
  35. Sagir, 2007, Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage, Hepatology, 47, 592, 10.1002/hep.22056 · DOI · Paper page
  36. Millonig, 2010, Liver stiffness is directly influenced by central venous pressure, J. Hepatol., 52, 206, 10.1016/j.jhep.2009.11.018 · DOI · Paper page
  37. Mueller, 2008, 17 Extrahepatic Cholestasis Increases Liver Stiffness (Fibroscan ®) Irrespective of Fibrosis, Gastroenterology, 134, 1718, 10.1016/S0016-5085(08)60013-X · doi:10.1016/s0016-5085(08)60013-x
  38. Cypierre, 2011, Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool, Amyloid, 18, 19, 10.3109/13506129.2010.543443 · DOI
  39. Lanzi, 2010, Liver AL amyloidosis as a possible cause of high liver stiffness values, Eur. J. Gastroenterol. Hepatol., 22, 895, 10.1097/MEG.0b013e3283309d5b · DOI
  40. Mueller, 2015, Inflammation-adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease, Liver Int., 35, 2514, 10.1111/liv.12904 · DOI · Paper page
  41. Mueller, 2010, Increased liver stiffness in alcoholic liver disease: Differentiating fibrosis from steatohepatitis, World J. Gastroenterol., 16, 966, 10.3748/wjg.v16.i8.966 · DOI · Paper page
  42. Mederacke, 2009, Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection, Liver Int., 29, 1500, 10.1111/j.1478-3231.2009.02100.x · DOI · Paper page
  43. Berzigotti, A., De Gottardi, A., Vukotic, R., Siramolpiwat, S., Abraldes, J.G., García-Pagan, J.C., and Bosch, J. (2013). Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension. PLoS ONE, 8. · DOI
  44. Arena, 2013, Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution, Hepatology, 58, 65, 10.1002/hep.26343 · DOI · Paper page
  45. Sasso, 2010, Controlled Attenuation Parameter (CAP): A Novel VCTE™ Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes, Ultrasound Med. Biol., 36, 1825, 10.1016/j.ultrasmedbio.2010.07.005 · DOI · Paper page
  46. Shi, 2014, Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: A meta-analysis of diagnostic accuracy, J. Gastroenterol. Hepatol., 29, 1149, 10.1111/jgh.12519 · DOI · Paper page
  47. Chan, 2014, Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease, J. Gastroenterol. Hepatol., 29, 1470, 10.1111/jgh.12557 · DOI · Paper page
  48. Darweesh, 2019, The clinical usefulness of elastography in the evaluation of nonalcoholic fatty liver disease patients, Eur. J. Gastroenterol. Hepatol., 31, 1010, 10.1097/MEG.0000000000001365 · DOI
  49. Caussy, 2018, Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis, Hepatology, 67, 1348, 10.1002/hep.29639 · DOI · Paper page
  50. Myers, 2012, Controlled Attenuation Parameter (CAP): A noninvasive method for the detection of hepatic steatosis based on transient elastography, Liver Int., 32, 902, 10.1111/j.1478-3231.2012.02781.x · DOI · Paper page
  51. Jung, K.S., Kim, B.K., Kim, S.U., Chon, Y.E., Cheon, K.H., Kim, S.B., Lee, S.H., Ahn, S.S., Park, J.Y., and Kim, D.Y. (2014). Factors Affecting the Accuracy of Controlled Attenuation Parameter (CAP) in Assessing Hepatic Steatosis in Patients with Chronic Liver Disease. PLoS ONE, 9. · DOI
  52. Wong, 2017, Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter, J. Hepatol., 67, 577, 10.1016/j.jhep.2017.05.005 · DOI
  53. Sasso, 2012, Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan (®): Validation in chronic hepatitis C, J Viral Hepat., 19, 244, 10.1111/j.1365-2893.2011.01534.x · DOI · Paper page
  54. Kumar, 2013, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis: Does etiology affect performance?, J. Gastroenterol. Hepatol., 28, 1194, 10.1111/jgh.12134 · DOI · Paper page
  55. Chon, 2013, Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: A prospective study of a native Korean population, Liver Int., 34, 102, 10.1111/liv.12282 · DOI · Paper page
  56. Shen, 2014, Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients, World J. Gastroenterol., 20, 4702, 10.3748/wjg.v20.i16.4702 · DOI
  57. Mi, 2014, Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B, Dig. Dis. Sci., 60, 243, 10.1007/s10620-014-3341-x · DOI
  58. Ratchatasettakul, K., Rattanasiri, S., Promson, K., Sringam, P., and Sobhonslidsuk, A. (2017). The inverse effect of meal intake on controlled attenuation parameter and liver stiffness as assessed by transient elastography. BMC Gastroenterol., 17. · DOI
  59. Silva, 2018, Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter, GE Port. J. Gastroenterol., 26, 99, 10.1159/000488505 · DOI
  60. Sasso, 2016, Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy, Ultrasound Med. Biol., 42, 92, 10.1016/j.ultrasmedbio.2015.08.008 · DOI
  61. Myers, 2011, Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients, Hepatology, 55, 199, 10.1002/hep.24624 · DOI · Paper page
  62. Wong, 2013, Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): Applying the cut-offs of M probe to XL probe, Ann. Hepatol., 12, 402, 10.1016/S1665-2681(19)31341-9 · DOI
  63. Sporea, 2014, Comparison between the M and XL probes for liver fibrosis assessment by Transient Elastography, Med Ultrason., 16, 119, 10.11152/mu.201.3.2066.162.rs1is2 · DOI
  64. Caussy, 2020, Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter with the M vs. the XL Probe in Patients with Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging–Proton Density Fat Fraction as the Standard, Clin. Gastroenterol. Hepatol., 18, 1842, 10.1016/j.cgh.2019.11.060 · DOI · Paper page
  65. Chan, 2018, Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?, J. Gastroenterol. Hepatol., 33, 1787, 10.1111/jgh.14150 · DOI
  66. Sumida, Y., Yoneda, M., Seko, Y., Ishiba, H., Hara, T., Toyoda, H., Yasuda, S., Kumada, T., Hayashi, H., and Kobayashi, T. (2020). Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics, 10. · doi:10.20944/preprints202007.0314.v1

Cited by

See all 123

Metadata

Authors
Oeda, S., Tanaka, K., Oshima, A., Matsumoto, Y., Sueoka, E., & Takahashi, H.
Venue
Diagnostics
Publisher
MDPI AG
Published
2020-11-12
Volume
10
Issue
11
Pages
940
ISSN
2075-4418 (ISSN-L)
OpenAlex
W3101045577
Cited by
123
References
6
FWCI
7.22
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.